Table 1 Clinical characteristics and co-morbidity of asthma patients before anti-IL5/IL5R and anti-IgE therapy
From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
Characteristics | Anti-IL5/IL5R, n = 42 | Anti-IgE, n = 22 |
|---|---|---|
Reslizumab, Mepolizumab, Benralizumab | Omalizumab | |
Time of use (months) | 12.79 (3–29. SD 8.49) | 49.41 (6–127. SD 35.34) |
Age (years) | 56 (32–73. SD 9.75) | 48 (28–76. SD 10.67) |
Women (number, (%)) | 23 (55) | 15 (68) |
Smokers (number, (%)) | 0 (0) | 0 (0) |
Ex-smokers (number, (%)) | 12 (29) | 2 (9) |
Body mass index (kg/m2) | 28.9 (16.9–39. SD 5.1) | 27.7 (20.4–36.8. SD 4.1) |
Nasal polyposis (number, (%)) | 31 (74) | 12 (55) |
Chronic rhinosinusitis (CRSwNP or CRSsNP) (number, (%)) | 39 (93) | 18 (82) |
Allergic rhinitis (number, (%)) | 12 (29) | 17 (77) |
ASA intolerance (number, (%)) | 9 (21) | 5 (23) |
Osteoporosis (number, (%)) | 16 (38) | 8 (36) |
Hypertension (number, (%)) | 20 (48) | 8 (36) |
Diabetes mellitus (number, (%)) | 3 (7) | 3 (14) |
Hypothyroidism (number, (%)) | 7 (17) | 3 (14) |
Coronary artery disease (number, (%)) | 1 (2) | 0 (0) |
Gastroesophageal reflux disease (number, (%)) | 10 (24) | 10 (45) |
Atrial fibrillation (number, (%)) | 3 (7) | 1 (5) |
Positive skin prick test or elevated allergen specific serum IgE (number, (%)) | 17 (40) | 22 (100) |
Pathological HRCT findings (number, (%)) a | 30 (71) | 14 (64) |
Patients with daily use of OCS (number, (%)) b | 30 (71) | 10 (45) |
Mean daily OCS dose before treatment (mg) | 7.07 (0–40. SD 7.13) | 4.82 (0–20. SD 6.50) |
Courses of OCS before treatment c | 4.21 (0–12. SD 2.75) | 2.50 (0–6. SD 1.56) |
Courses of antibiotics before treatment c | 1.40 (0–5. SD 1.42) | 0.95 (0–3. SD 0.93) |
Emergency room visits before treatment c | 0.62 (0–8. SD 1.51) | 0.18 (0–1. SD 0.39) |
Sick leaves before treatment c | 0.93 (0–6. SD 1.72) | 0.59 (0–4. SD 1.03) |
Hospitalisations before treatment c | 0.52 (0–8. SD 1.42) | 0.45 (0–2. SD 0.66) |
FEV1 (mean) before treatment (litres) | 2.27 (0.99–4.18. SD 0.78) | 2.83 (1.5–4.2. SD 0.86) |
FVC (mean) before treatment (litres) | 3.38 (1.71–5.25. SD 0.99) | 3.82 (2.1–5.8. SD 0.85) |
FEV1/FVC (mean) before treatment | 0.67 (0.42–0.91. SD 0.12) | 0.74 (0.48–0.91. SD 0.13) |
Blood eosinophil count (mean) before treatment (E9/litre) | 0.45 (0.03–1.84. SD 0.37) | 0.43 (0–1.34. SD 0.41) |
Exhaled nitric oxide (mean) (ppb) | 28.17 (5–110. SD 28.98) | 35.66 (5–123. SD 36.30) |
Serum total IgE (mean) (kU/litre) | 290.85 (8–4672. SD 786.18) | 313.36 (14–720. SD 248.76) |
ACT (mean) d | 15.6 (8–23. SD 4.28) | 13.4 (7–22. SD 4.82) |